These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7051074)

  • 1. Physostigmine in the treatment of memory disorders: a case report.
    Denber HC
    Psychiatr J Univ Ott; 1982 Mar; 7(1):8-12. PubMed ID: 7051074
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of physostigmine and lecithin on memory in Alzheimer disease.
    Peters BH; Levin HS
    Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral physostigmine and lecithin improve memory in Alzheimer disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS
    Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug combination may improve memory.
    Geriatrics; 1979 Oct; 34(10):15. PubMed ID: 478303
    [No Abstract]   [Full Text] [Related]  

  • 6. Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's disease.
    N Engl J Med; 1983 Sep; 309(9):555-6. PubMed ID: 6877328
    [No Abstract]   [Full Text] [Related]  

  • 7. Physostigmine and its effect on six patients with dementia.
    Ashford JW; Soldinger S; Schaeffer J; Cochran L; Jarvik LF
    Am J Psychiatry; 1981 Jun; 138(6):829-30. PubMed ID: 7246817
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term outpatient treatment of senile dementia with oral physostigmine.
    Beller SA; Overall JE; Rhoades HM; Swann AC
    J Clin Psychiatry; 1988 Oct; 49(10):400-4. PubMed ID: 3049561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory enhancement with oral physostigmine in Alzheimer's disease.
    N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
    Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
    Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
    Christie JE; Shering A; Ferguson J; Glen AI
    Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical approaches to the treatment of senile dementia.
    Growdon JH; Corkin S
    Proc Annu Meet Am Psychopathol Assoc; 1980; 69():281-96. PubMed ID: 7413654
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose-related physostigmine-induced ventricular arrhythmia: case report.
    Dysken MW; Janowsky DS
    J Clin Psychiatry; 1985 Oct; 46(10):446-7. PubMed ID: 4044537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of physostigmine on amnesic syndromes (author's transl)].
    Laurent B; Hibert-Kuntzler O; Chazot G; Michel D; Schott B
    Rev Neurol (Paris); 1981; 137(11):649-60. PubMed ID: 7336018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dementia.
    Warner J; Butler R; Arya P
    Clin Evid; 2004 Dec; (12):1361-90. PubMed ID: 15865724
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia.
    Caltagirone C; Gainotti G; Masullo C
    Int J Neurosci; 1982 May; 16(3-4):247-9. PubMed ID: 7169287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of choline on amnesia in early Alzheimer's disease.
    Signoret JL; Whiteley A; Lhermitte F
    Lancet; 1978 Oct; 2(8094):837. PubMed ID: 81385
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers Presenile Dementia.
    Caltagirone C; Albanese A; Gainotti G; Masullo C
    Int J Neurosci; 1983; 18(1-2):143-7. PubMed ID: 6840979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psychopharmacologic treatment of cognitive function disorders in aging persons: current possibilities].
    Jolles J; Verhoeven WM
    Tijdschr Gerontol Geriatr; 1984 Aug; 15(4):139-50. PubMed ID: 6091299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin and physostigmine in the treatment of amnesia.
    Franceschi M; Tancredi O; Savio G; Smirne S
    Eur Neurol; 1982; 21(6):388-91. PubMed ID: 6756927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.